Kangmei Pharmaceutical Co., LtdSSE: 600518

Announcement on Progress of Litigation Involved (II)

· Issued by Kangmei Pharmaceutical Co., Ltd via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Kangmei Pharmaceutical Co., Ltd has announced the progress of ongoing litigation involving the company, detailing the current status and implications for its financials. The company is currently a respondent in an appeal case where the initial judgment required it to compensate a significant number of investors. The filing highlights that the outcome of the appeal remains uncertain, and the company cannot predict the impact on its profits at this time.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Kangmei Pharmaceutical Co., Ltd on 6ix

Earlier from Kangmei Pharmaceutical

Later from Kangmei Pharmaceutical

All Kangmei Pharmaceutical news releases